Vivace Therapeutics is an oncology-focused small molecule drug discovery and development company.
Location: United States, California, Princeton-by-the-Sea
Employees: 11-50
Total raised: $105M
Founded date: 2014
Investors 5
| Date | Name | Website |
| - | Cenova Cap... | cenova.com |
| - | Mission Bi... | missionbio... |
| - | 6 Dimensio... | 6dimension... |
| - | RA Capital... | racap.com |
| - | Canaan Par... | canaan.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 14.03.2025 | Series D | $35M | - |
| 17.12.2020 | Series C | $30M | - |
| 28.06.2017 | Series A | $40M | - |
Mentions in press and media 9
| Date | Title | Description |
| 15.03.2025 | Vivace Therapeutics Secures $35 Million to Propel Cancer Drug Development | Vivace Therapeutics is on the rise. The San Mateo-based company has just secured $35 million in Series D financing. This funding round was led by RA Capital Management, a familiar face in Vivace's journey. Other notable investors, including... |
| 14.03.2025 | Vivace Therapeutics: $35 Million (Series D) Raised For Supporting Development Of Cancer Drug Targeting Hippo Pathway | Vivace Therapeutics – a small molecule discovery and development company developing first-in-class cancer therapies targeting the Hippo pathway – announced the closing of a $35 million Series D financing. The funding round was led by RA Cap... |
| 12.03.2025 | Vivace Therapeutics Raises $35M in Series D Financing | Vivace Therapeutics, a San Mateo, CA-based small molecule discovery and development company, raised $35M in Series D funding. The round was led by RA Capital Management, an existing investor, and included investment from other existing inve... |
| 16.04.2023 | Researchers Report Clinical Proof-of-Concept Data for Vivace Therapeutics' VT3989, a First for a Cancer Drug Targeting the Hippo Pathway, in Oral Presentation at AACR 2023 | First-in-Class TEAD Autopalmitoylation Inhibitor is Well Tolerated and Demonstrates Antitumor Activity in Advanced Mesothelioma and NF2-Mutant Cancers VT3989 is the First Therapeutic Targeting the Hippo Pathway to Demonstrate Clinical Activ... |
| 17.12.2020 | Endpoints News: Vivace Therapeutics scores $30M Series C to take oncology candidate for 'Hippo' pathway to human trial next year | - |
| 17.12.2020 | Vivace Therapeutics Raises $30M in Series C Financing | Vivace Therapeutics, Inc., a San Mateo, CA-based small molecule discovery and development company developing first-in-class therapies targeting the Hippo pathway, closed a $30m Series C financing. The round was led by Boxer Capital with par... |
| 16.12.2020 | Vivace Therapeutics Announces $30 Million Series C Financing to Fund Clinical Programs Targeting the Hippo Pathway | SAN MATEO, Calif., Dec. 16, 2020 /PRNewswire/ -- Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class therapies targeting the Hippo pathway, announced today the closing of a $30 million Ser... |
| 28.06.2017 | Vivace Therapeutics Raises $40M in Series A and Series B Funding | Vivace Therapeutics, a San Mateo, Calif.-based oncology-focused portfolio-based drug discovery and development company, is coming out of stealth with $40m in Series A and B financings. The $25 million Series B was led by new investor Cenova... |
| - | Vivace Therapeutics | “Home | Vivace” |